BLAINJECTIONINJECTABLE
Approved
Feb 2024
Lifecycle
Growth
Competitive Pressure
30/100
Data completeness
4/8 — Partial
SIMLANDI (adalimumab-ryvk) by Alvotech is tnf-alpha and block its interaction with the p55 and p75 cell surface tnf receptors. Approved for rheumatoid arthritis, ulcerative colitis, crohn's disease and 6 more indications. First approved in 2024.
Drug data last refreshed 19h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SIMLANDI (adalimumab-ryvk) is a TNF-alpha inhibitor monoclonal antibody approved in February 2024 by Alvotech as a biosimilar to reference HUMIRA. It blocks TNF-alpha interaction with cell surface receptors, reducing inflammation across rheumatologic and gastroenterologic indications. The drug treats nine approved indications including rheumatoid arthritis, psoriasis, Crohn's disease, ulcerative colitis, and ankylosing spondylitis.
Growth
Recently approved biosimilar in growth phase competing against a mature, declining reference product, with moderate competitive pressure (30/100) suggesting team expansion opportunity for commercial and manufacturing roles.
Mechanism of Action
TNF-alpha and block its interaction with the p55 and p75 cell surface TNF receptors. Adalimumab products also lyse surface TNF expressing cells in vitro in the presence of complement. Adalimumab products do not bind or inactivate lymphotoxin (TNF-beta). TNF is a naturally occurring cytokine that is…
Indications (9)
Worked on SIMLANDI at Alvotech? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.